Strategies to address mesenchymal stem/stromal cell heterogeneity in immunomodulatory profiles to improve cell-based therapies

• Published in: Acta biomaterialia Vol. 133; pp. 114 - 125
• Main Authors: Dunn, Celia M., Kameishi, Sumako, Grainger, David W., Okano, Teruo
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.10.2021; Elsevier BV
• Subjects: Autografts; Clinical trials; Clonal selection; Critical quality attributes; Cytokines; Graft-versus-host reaction; Heterogeneity; Immune system; Immunological tolerance; Immunomodulation; Mesenchyme; Potency; Priming; Product release criteria; Quality control; Stromal cells; Therapeutic efficacy; Critical quality attributes; Quality control; Therapeutic efficacy; Priming; Clonal selection; Potency; Product release criteria
• ISSN: 1742-7061; 1878-7568
• DOI: 10.1016/j.actbio.2021.03.069

Mesenchymal stromal cells (MSCs) have gained immense attention over the past two decades due to their multipotent differentiation potential and pro-regenerative and immunomodulatory cytokine secretory profiles. Their ability to modulate the host immune system and promote tolerance has prompted several allogeneic and autologous hMSC-based clinical trials for the treatment of graft-versus-host disease and several other immune-induced disorders. However, clinical success beyond safety is still controversial and highly variable, with inconclusive therapeutic benefits and little mechanistic explanation. This clinical variability has been broadly attributed to inconsistent MSC sourcing, phenotypic characterization, variable potency, and non-standard isolation protocols, leading to functional heterogeneity among administered MSCs. Homogeneous MSC populations are proposed to yield more predictable, reliable biological responses and clinically meaningful properties relevant to cell-based therapies. Limited comparisons of heterogeneous MSCs with homogenous MSCs are reported. This review addresses this gap in the literature with a critical analysis of strategies aimed at decreasing MSC heterogeneity concerning their reported immunomodulatory profiles. This review collates, summarizes, and critically analyzes published strategies that seek to improve homogeneity in immunomodulatory functioning MSC populations intended as cell therapies to treat immune-based disorders, such as graft-vs-host-disease. No such review for MSC therapies, immunomodulatory profiles and cell heterogeneity analysis is published. Since MSCs represent the most clinically studied experimental cell therapy platform globally for which there remains no US domestic marketing approval, insights into MSC challenges in therapeutic product development are imperative to providing solutions for immunomodulatory variabilities. [Display omitted]